Jorge Plutzky - Department of Medicine

Jorge Plutzky

View Physician Profile

Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Cardiovascular
75 Francis Street
Boston, MA 02115

Education:	Unicersity of North Carolina School of Medicine, 1986, MD

Keywords (MeSH):	Thiazolidinediones Receptors, Cytoplasmic and Nuclear Peroxisome Proliferator-Activated Receptors Arteriosclerosis Diabetic Angiopathies PPAR alpha

Publications (Pulled from Harvard Catalyst Profiles): 1. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013 Apr 2; 158(7):526-34. 2. Rosenson RS, Wright RS, Farkouh M, Plutzky J. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J. 2012 Nov; 164(5):672-80. 3. Kiefer FW, Cohen P, Plutzky J. Fifty shades of brown: perivascular fat, thermogenesis, and atherosclerosis. Circulation. 2012 Aug 28; 126(9):1012-5. 4. de Ferranti SD, Daniels SR, Gillman M, Vernacchio L, Plutzky J, Baker AL. NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction: Can We Clarify the Controversy about Cholesterol Screening and Treatment in Childhood? Clin Chem. 2012 Dec; 58(12):1626-30. 5. Rhee EJ, Plutzky J. Retinoid metabolism and diabetes mellitus. Diabetes Metab J. 2012 Jun; 36(3):167-80. 6. Kiefer FW, Vernochet C, O'Brien P, Spoerl S, Brown JD, Nallamshetty S, Zeyda M, Stulnig TM, Cohen DE, Kahn CR, Plutzky J. Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue. Nat Med. 2012 Jun; 18(6):918-25. 7. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. J Infect Dis. 2012 Jun; 205 Suppl 3:S368-74. 8. Elmasri H, Ghelfi E, Yu CW, Traphagen S, Cernadas M, Cao H, Shi GP, Plutzky J, Sahin M, Hotamisligil G, Cataltepe S. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis. 2012 Sep; 15(3):457-68. 9. Kiefer FW, Orasanu G, Nallamshetty S, Brown JD, Wang H, Luger P, Qi NR, Burant CF, Duester G, Plutzky J. Retinaldehyde dehydrogenase 1 coordinates hepatic gluconeogenesis and lipid metabolism. Endocrinology. 2012 Jul; 153(7):3089-99. 10. Jain M, Plutzky J. Commentary. Clin Chem. 2012 May; 58(5):829-30. show all 11. Plutzky J. The incretin axis in cardiovascular disease. Circulation. 2011 Nov 22; 124(21):2285-9. 12. Shetty S, Ramos-Roman MA, Cho YR, Brown J, Plutzky J, Muise ES, Horton JD, Scherer PE, Parks EJ. Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology. 2012 Jan; 153(1):113-22. 13. Skentzos S, Shubina M, Plutzky J, Turchin A. Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. AMIA Annu Symp Proc. 2011; 2011:1270-9. 14. Shabrova EV, Tarnopolsky O, Singh AP, Plutzky J, Vorsa N, Quadro L. Insights into the molecular mechanisms of the anti-atherogenic actions of flavonoids in normal and obese mice. PLoS One. 2011; 6(10):e24634. 15. Blaser BW, Kim HT, Alyea EP, Ho VT, Cutler C, Armand P, Koreth J, Antin JH, Plutzky J, Soiffer RJ. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83. 16. Plutzky J. Macrovascular effects and safety issues of therapies for type 2 diabetes. Am J Cardiol. 2011 Aug 2; 108(3 Suppl):25B-32B. 17. Davidson MH, Plutzky J. The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. Am J Cardiol. 2011 Aug 2; 108(3 Suppl):1B-2B. 18. Rhee EJ, Nallamshetty S, Plutzky J. Retinoid metabolism and its effects on the vasculature. Biochim Biophys Acta. 2012 Jan; 1821(1):230-40. 19. Brown JD, Oligino E, Rader DJ, Saghatelian A, Plutzky J. VLDL hydrolysis by hepatic lipase regulates PPARd transcriptional responses. PLoS One. 2011; 6(7):e21209. 20. Lee JH, Giannikopoulos P, Duncan SA, Wang J, Johansen CT, Brown JD, Plutzky J, Hegele RA, Glimcher LH, Lee AH. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med. 2011 Jul; 17(7):812-5. 21. Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Hrabé de Angelis M, Schlederer M, Mair M, Kenner L, Plutzky J, Zeyda M, Stulnig TM. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia. 2011 Aug; 54(8):2132-42. 22. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res. 2011 Apr 15; 108(8):1002-16. 23. Chang K, Francis SA, Aikawa E, Figueiredo JL, Kohler RH, McCarthy JR, Weissleder R, Plutzky J, Jaffer FA. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol. 2010 Oct; 30(10):1933-9. 24. Fonseca VA, Zinman B, Nauck MA, Goldfine AB, Plutzky J. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. Am J Med. 2010 Jul; 123(7):S2-S10. 25. Ruby MA, Goldenson B, Orasanu G, Johnston TP, Plutzky J, Krauss RM. VLDL hydrolysis by LPL activates PPAR-alpha through generation of unbound fatty acids. J Lipid Res. 2010 Aug; 51(8):2275-81. 26. Chutkow WA, Birkenfeld AL, Brown JD, Lee HY, Frederick DW, Yoshioka J, Patwari P, Kursawe R, Cushman SW, Plutzky J, Shulman GI, Samuel VT, Lee RT. Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes. 2010 Jun; 59(6):1424-34. 27. Brown J, Nallamshetty S, Plutzky J. Intersecting vectors of basic science research and clinical medicine: LOX-1? Clin Chem. 2010 Apr; 56(4):499-501. 28. Plutzky J. Expansion and contraction: the mighty, mighty fatty acid. Nat Med. 2009 Jun; 15(6):618-9. 29. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009 Feb 3; 53(5 Suppl):S35-42. 30. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, Michel T, Plutzky J. PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest. 2009 Jan; 119(1):110-24. 31. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008 Nov 17; 102(10 Suppl):1K-34K. 32. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008 Nov; 5(4):319-35. 33. Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol. 2008 Sep 2; 52(10):869-81. 34. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008 May 24; 371(9626):1800-9. 35. Paruchuri S, Jiang Y, Feng C, Francis SA, Plutzky J, Boyce JA. Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem. 2008 Jun 13; 283(24):16477-87. 36. Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus: proceeding with caution at a dangerous intersection. J Am Soc Nephrol. 2008 Jan; 19(1):4-7. 37. Plutzky J. A cardiologist's perspective on cardiometabolic risk. Am J Cardiol. 2007 Dec 17; 100(12A):3P-6P. 38. Ziouzenkova O, Plutzky J. Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett. 2008 Jan 9; 582(1):32-8. 39. Plutzky J. Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha. Diab Vasc Dis Res. 2007 Sep; 4 Suppl 3:S12-4. 40. Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med. 2007 Aug; 262(2):184-98. 41. Ziouzenkova O, Orasanu G, Sharlach M, Akiyama TE, Berger JP, Viereck J, Hamilton JA, Tang G, Dolnikowski GG, Vogel S, Duester G, Plutzky J. Retinaldehyde represses adipogenesis and diet-induced obesity. Nat Med. 2007 Jun; 13(6):695-702. 42. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta. 2007 Aug; 1771(8):972-82. 43. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007 Jan 30; 115(4):518-33. 44. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007 Jan; 30(1):162-72. 45. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007 Jan 2; 115(1):114-26. 46. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol. 2007 Feb 19; 99(4A):27B-40B. 47. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006 Dec 19; 114(25):2871-91. 48. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006 Dec 19; 114(25):2850-70. 49. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006 Dec; 58(4):726-41. 50. Ziouzenkova O, Orasanu G, Sukhova G, Lau E, Berger JP, Tang G, Krinsky NI, Dolnikowski GG, Plutzky J. Asymmetric cleavage of beta-carotene yields a transcriptional repressor of retinoid X receptor and peroxisome proliferator-activated receptor responses. Mol Endocrinol. 2007 Jan; 21(1):77-88. 51. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J, Chait A. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol. 2006 Aug; 26(8):1806-13. 52. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Ziouzenkova O, Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res. 2006 Mar 3; 98(4):490-8. 53. Lee CH, Plutzky J. Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune? Circulation. 2006 Jan 3; 113(1):5-8. 54. Oligino E, Ziouzenkova O, Plutzky J. . VLDL hydrolysis by hepatic lipase is a distinct mechanism for PPAR-delta activation. Sarnoff Endowment, Washington, DC. 2006. 55. Gornik HL, Plutzky J. . Dyslipidemia. In: Gaziano JM, editor. Atlas of Cardiovascular Risk Factors. 2005; 97-114. 56. McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF. Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. Diabetes Care. 2005 May; 28(5):1145-50. 57. Plutzky J, Ziouzenkova O. . Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions. 2005. 58. Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord. 2005; 3(2):147-73. 59. Plutzky J. . Peroxisome proliferator-activated receptors in diabetes, vascular inflammation, and atherosclerosis (DVD, audio tape). 2005. 60. Orasanu G, Ziouzenkova O, Plutzky J. . Peroxisome proliferator activated receptors (PPARs) – potential targets for diabetic atherosclerosis. In: Cheta D, editor. Vascular Involvement in Diabetes. 2005; 35-49. 61. Devchand PR, Ziouzenkova O, Plutzky J. Oxidative stress and peroxisome proliferator-activated receptors: reversing the curse? Circ Res. 2004 Dec 10; 95(12):1137-9. 62. Plutzky J. Inflammation in atherosclerosis and diabetes mellitus. Rev Endocr Metab Disord. 2004 Aug; 5(3):255-9. 63. Ziouzenkova O, Plutzky J. Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation? Curr Opin Clin Nutr Metab Care. 2004 Jul; 7(4):369-75. 64. Plutzky J. PPARs: altering clinical responses in Type 2 diabetes and atherosclerosis. Introduction. Clin Cardiol. 2004 Jul; 27(7 Suppl 4):IV1-2. 65. Orasanu G, Ziouzenkova O, Ahmed W, Shoelson S, Plutzky J. Lipoprotein metabolism and uptake direct divergent peroxisome proliferator-activated receptor-? and hepatocyte nuclear factor 4? responses. American Heart Association Scientific Sessions, New Orleans, LA. 2004. 66. Ziouzenkova O, Plutzky J. . Exogenous and endogenous mechanisms of PPAR activation: implications for inflammation and atherosclerosis. International Congress Series. 2004; 1262:147-151. 67. Ahmed W, Ziouzenkova O, Orasanu G, Marchadier D, Rader D, Plutzky J. . Endothelial lipase acts on HDL to activate PPAR?. American Heart Association Scientific Sessions, New Orleans, LA. 2004. 68. Plutzky J. The vascular biology of atherosclerosis. Am J Med. 2003 Dec 8; 115 Suppl 8A:55S-61S. 69. Plutzky J. Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. J Am Coll Cardiol. 2003 Nov 19; 42(10):1764-6. 70. Beckman J, Raji A, Plutzky J. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. Curr Opin Cardiol. 2003 Nov; 18(6):479-85. 71. Plutzky J. Medicine. PPARs as therapeutic targets: reverse cardiology? Science. 2003 Oct 17; 302(5644):406-7. 72. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol. 2003 Aug 18; 92(4A):34J-41J. 73. Ziouzenkova O, Asatryan L, Sahady D, Orasanu G, Perrey S, Cutak B, Hassell T, Akiyama TE, Berger JP, Sevanian A, Plutzky J. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem. 2003 Oct 10; 278(41):39874-81. 74. Plutzky J. . PPARs and atherosclerosis. In: Duttaroy AK, Spener F, editors. Cellular proteins and their fatty acids in health and disease. 2003; Chapter 23. 75. Plutzky J. Diabetes as a vascular disease. Dyslipidemia as a target. Postgrad Med. 2003 Apr; 113(4 Suppl):15-23. 76. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, Zee RY. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003 May 1; 23(5):859-63. 77. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, Rader DJ, Sevanian A, Zechner R, Hoefler G, Plutzky J. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A. 2003 Mar 4; 100(5):2730-5. 78. Kramer D, Raji A, Plutzky J. Prediabetes mellitus and its links to atherosclerosis. Curr Diab Rep. 2003 Feb; 3(1):11-8. 79. Plutzky J. . PPARs. In: Izzo JL, Black HR, editors. Hypertension Primer. 2003; 60-62. 80. Plutzky J, Libby P. . Pathophysiology of atherosclerotic heart disease. In: Tonkin AM, editor. Atherosclerosis and Heart Disease. 2003; 1-12. 81. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation. 2002 Nov 26; 106(22):2760-3. 82. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications. 2002 Nov-Dec; 16(6):401-15. 83. Raji A, Plutzky J. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep. 2002 Nov; 4(6):514-21. 84. Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood. 2002 Aug 15; 100(4):1340-6. 85. Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002 Apr 5; 90(6):703-10. 86. Ziouzenkova O, Perrey S, Marx N, Bacqueville D, Plutzky J. Peroxisome proliferator-activated receptors. Curr Atheroscler Rep. 2002 Jan; 4(1):59-64. 87. Plutzky J. . The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease. Am J Cardiol. 2002; 90(7 ): 139-143. 88. Plutzky J, Libby P. . Diabetes and cardiovascular disease (DVD). 2002. 89. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol. 2001 Oct 18; 88(8A):10K-15K. 90. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol. 2001 Oct; 12(5):511-8. 91. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk. 2001 Aug; 8(4):203-10. 92. Plutzky J, Davidson J. . Diabetes and cardiovascular disease in the Hispanic population, (CD-ROM). 2001. 93. Plutzky J, Ridker PM. Statins for stroke: the second story? Circulation. 2001 Jan 23; 103(3):348-50. 94. Marx N, Mackman N, Schönbeck U, Yilmaz N, Hombach V, Libby P, Plutzky J. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation. 2001 Jan 16; 103(2):213-9. 95. Plutzky J. . Insulin resistance and atherosclerosis. 2001. 96. Plutzky J. . PPARs and diabetic atherosclerosis. 2001. 97. Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol. 2000 Nov; 15(6):416-21. 98. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep. 2000 Jul; 2(4):327-35. 99. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000 Jun 15; 164(12):6503-8. 100. Plutzky J. . PPARs and diabetic atherosclerosis. 2000. 101. Plutzky J, Libby P, Nakamura H. Second annual US/Japanese dialogue on lipids and atherosclerosis: towards an understanding of mechanism. 2000. 102. Libby P, Aikawa M, Schoenbeck U, Sukhova G, Mach F, Marx N, Plutzky J. . Inflammation and plaque stability. In: Stemme S, Olsson AG, editors. Atherosclerosis XII. 2000; 67-80. 103. Plutzky J. . Atherosclerosis: an insulin resistance disorder. Proceedings from the Second Annual US/Japanese Dialogue on Lipids and Atherosclerosis. 2000; 245:49-58. 104. Libby P, Aikawa M, Schönbeck U, Sukhova G, Mach F, Marx N, Plutzky J. . Inflammation and plaque stability. 2000. 105. Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk. 1999 Oct; 6(5):337-46. 106. Kinlay S, Plutzky J. Effect of lipid-lowering therapy on vasomotion and endothelial function. Curr Cardiol Rep. 1999 Sep; 1(3):238-43. 107. Plutzky J. Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol. 1999 Jul 8; 84(1A):15J-20J. 108. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999 Jun 22; 99(24):3125-31. 109. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999 Mar; 19(3):546-51. 110. Plutzky J. . Coronary artery disease in the younger patient. New issues for the next millennium. 1999; 238:75-83. 111. Plutzky J. . Making sense of clinical trials in lipid lowering. Intensive review of internal medicine (CD-ROM). 1999. 112. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998 Nov 30; 83(11):1097-103. 113. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol. 1998 Jul; 153(1):17-23. 114. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 Mar 31; 97(12):1129-35. 115. Plutzky J. . Myocardial infarction in the younger patient. Cannon CP, editor. Management of acute coronary syndrome. 1998; 653-666. . 116. Plutzky J. . Disorders of the heart and vascular system. Harrison’s Principles of Internal Medicine Self-Assessment and Review. 1998; 49-90. . 117. Blumnethal RS, Plutzky J. Secondary prevention of myocardial infarction. Cannon CP, editor. Management of acute coronary syndrome. 1998; 695-704. 118. Oberg K, Cannon C, Plutzky J. Focus on reteplase: a newly approved third-generation thrombolytic agent for the treatment of acute myocardial infarction. Formulary. 1997; 32:37-45. 119. Freeman R, Plutzky J, Neel B, Rosenberg R. Methods for identifying a tyrosine phosphatase abnormally associated with neoplastic disease. 1996. 120. Neel BG, Plutzky J, Rosenberg RD, Freeman RM, Lorenz U, Lechleider RJ. . Molecular cloning and characterization of a subfamily of nontransmembrane PTPs containing src homology 2 (SH2) domains. Adv Protein Phosphatases. 1993; 7:127-151. 121. Freeman RM, Plutzky J, Neel BG. Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. Proc Natl Acad Sci U S A. 1992 Dec 1; 89(23):11239-43. 122. Plutzky J, Neel BG, Rosenberg RD, Eddy RL, Byers MG, Jani-Sait S, Shows TB. Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). Genomics. 1992 Jul; 13(3):869-72. 123. Plutzky J, Neel BG, Rosenberg RD. Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A. 1992 Feb 1; 89(3):1123-7. 124. Plutzky J. On being a physician. Am J Med. 1990 Aug; 89(2):252. 125. Plutzky J, Hoskins JA, Long GL, Crabtree GR. Evolution and organization of the human protein C gene. Proc Natl Acad Sci U S A. 1986 Feb; 83(3):546-50. 126. Beckmann RJ, Schmidt RJ, Santerre RF, Plutzky J, Crabtree GR, Long GL. The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. Nucleic Acids Res. 1985 Jul 25; 13(14):5233-47.

Send Feedback to the BWH Biomedical Research Institute.

EDIT YOUR PROFILE

Department

View all Research Faculty in the Department of Medicine

Division

View all Research Faculty: Cardiovascular

BRI Research Center/Program Affiliation(s)

Cardiovascular, Diabetes and Metabolic Disorders Research Center